b'READ MORE 2 0 1 9 Full articles available P r e s s H i g h l i g h t s online at invivoscribe.comMAY 21, 2019Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic MalignanciesInvivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics, today announces expansion of space and testing capabilities in their international network of accredited LabPMM clinical laboratories. Additions to the test menu will include morphology, IHC, flow cytometry, as well as the latest multiparameter flow- (MPF), and NGS-based minimal residual disease (MRD) testing of primary specimens. These new services will further support rapid patient diagnosis, study subject enrollment, and study subject stratifications. They will be available by end of this year in San Diego followed by the laboratories in Japan, Germany and China.JUNE 19, 2019Japans MHLW Approves Invivoscribes LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyos Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTAInvivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyos Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. DECEMBER 05, 2019The European Commission Approves Astellas XOSPATA for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation AssayFor twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. The LeukoStrat CDx FLT3 Mutation Assay may now be used as an aid in the assessment of AML patients for treatment with XOSPATA (gilteritinib) in Europe. FLT3 mutation must be confirmed with a validated test, such as the LeukoStrat CDx FLT3 Mutation Assay, which served as the companion diagnostic in the Phase 3 ADMIRAL trial resulting in approval of XOSPATA.Companion diagnostics play a key role in the development and approval of targeted drug therapies. The ability to screen for biomarkers in a patient population creates patient subsets which further enables drug developers in the design of novel therapeutics and management of clinical trials. Accordingly, the successful approval of a targeted therapy is highly dependent on the performance of the companion diagnostic.2 0 1 9P r o d u c t H i g h l i g h t sAUGUST 26, 2019NOW AVAILABLE! MRD solutions for B- and T-cell clonality trackingMinimal Residual Disease (MRD) is the presence of low levels of malignant cells that remain in a subject during or after treatment or when the patient is in remission. Detectable levels of cancer cells following treatment may suggest a higher probability of relapse.Invivoscribe 2020|7'